---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-095437"
form_type: "8-K"
ticker: "ZBIO"
cik: "0001953926"
company_name: "Zenas BioPharma, Inc."
filed_at: "2026-08-13T11:05:49+00:00"
generated_at: "2026-08-13T11:10:23.362954+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Zenas Q2 net loss $111.5M; FDA accepts obexelimab BLA, PDUFA May 27, 2027

## Summary
- Q2 2026 net loss $111.5M vs $52.2M; revenue $1.0M from Tenacia milestone; R&D $62.9M, G&A $15.7M, AIPR&D $30.0M.
- Cash $673.9M at June 30; runway through Q2 2029 assuming $75M Royalty Pharma milestone and $75M Pharmakon draw.
- FDA accepted obexelimab BLA for IgG4-RD; PDUFA May 27, 2027; MAA to EMA expected H2 2026.
- Phase 3 INDIGO: 56% flare risk reduction (HR 0.44, p=0.0005); 73.2% flare-free vs 45.4% placebo.
- CFO Jennifer Fox to become Strategic Advisor to Board Chair Sept 30; Joe Farmer named Principal Financial Officer.

## SEC filing metadata
- accession: 0001104659-26-095437
- form_type: 8-K
- ticker: ZBIO
- cik: 0001953926
- company_name: Zenas BioPharma, Inc.
- filed_at: 2026-08-13T11:05:49+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1953926/000110465926095437/0001104659-26-095437-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1953926/000110465926095437/tm2622871d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-095437
- JSON: https://secwatch.observer/filing/0001104659-26-095437.json
- Plain text: https://secwatch.observer/filing/0001104659-26-095437.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.